FDA Puts Hold on Plans to Start Clinical Testing of DNL919 Therapy

Home / Alzheimer's / FDA Puts Hold on Plans to Start Clinical Testing of DNL919 Therapy
FDA Puts Hold on Plans to Start Clinical Testing of DNL919 Therapy
January 21, 2022January 21, 2022
0

The U.S. Food and Drug Administration (FDA) has put a clinical hold Denali Therapeutics’ application to begin clinical testing of DNL919, an immune-modulating medication that the company is developing to treat Alzheimer’s disease. The FDA will issue an official clinical hold letter to Denali in the next month or so, according to a company press release. Denali had been hoping to start clinical testing of DNL919 in the first half of this year. The company said…

You must be logged in to read/download the full post.

The post FDA Puts Hold on Plans to Start Clinical Testing of DNL919 Therapy appeared first on BioNewsFeeds.